Neuravi produces the EmboTrap and EmboTrap II revascularization platforms designed capture clots and allow blood flow to resume immediately after the clot has been secured in patients who have experienced a stroke.
J&J’s Codman Neuro said that the acquisition, along with its recent Pulsar Vascular buy, demonstrates the company’s “strong commitment to delivering innovative products for stroke therapy,” according to a press release.
“Rapid restoration of flow is of utmost importance when treating stroke patients. The EmboTrap platform was designed to address this critical need and we are excited to combine Neuravi’s expertise in clot research with Codman Neuro’s global resources to accelerate innovation in acute ischemic stroke treatment,” J&J medical devices cardiovascular & specialty solutions group chair Shlomi Nachman said in a prepared statement.
Neuravi’s EmboTrap and EmboTrap II revascularization devices have won CE Mark clearance in the European Union and are currently under investigational use in the US, with a clinical trial in progress to support FDA submission later this year.